Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor

AIDS

Volumn 12, Issue 16, 1998, Pages 2161-2167

  Mocroft, Amanda ^a   Gill, M John ^b,c   Davidson, William ^b   Phillips, Andrew N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Progression; Protease inhibitors; Undetectability; Viral load

Indexed keywords

CD4 ANTIGEN; INDINAVIR; PROTEINASE INHIBITOR;

ADULT; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NONHUMAN; PREDICTION; PRIORITY JOURNAL; STATISTICAL MODEL; SURVIVAL; TREATMENT FAILURE; VIRUS LOAD;

EID: 0032511917     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199816000-00011     Document Type: Article

References (33)

1. Yerly S, Perneger TV, Hirschel B, et al.: A critical assessment of the prognostic value of HIV-1 RNA levels and CD4+ cell counts in HIV-infected patients. Arch Intern Med 1998, 158:247-252.
2. Vlahov D, Graham N, Hoover D, et al.: Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA 1998, 279:35-40.
3. Marschner IC, Collier AC, Coombs RW, et al.: Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998, 177:40-47.
4. Havlir DV, Richmann DD: Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann Intern Med 1996, 124:984-994.
5. Feinberg M: Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997, 349:1408-1409.
6. BHIVA Guidelines Coordinating Committee: British HIV association guidelines for antiretroviral treatment of seropositive individuals. Lancet 1997, 349:1086-1092.
7. Carpenter CCJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997, 277:1962-1969.
8. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
9. Forrest DM, Seminari E, Montaner JSG, et al.: Changing incidence and spectrum of AIDS-defining illnesses (ADIs) in the modern antiretroviral era. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 179].
10. Murphy R, El-Sadr W, Cheung T, et al.: Impact of protease inhibitor containing regimens on the risk of developing opportunistic infections and mortality in the CPCRA 0134/ACTG 277 study. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 181].
11. Hammer S, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-731.
12. Gullick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
13. Collier AC, Coombs RW, Schoenfield DA, et al.: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996, 334:1011-1017.
14. Egger M, Hirschel B, Francioli P, et al.: Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997, 315:1194-1199.
15. Centers for Disease Control and Prevention: Update: trends in AIDS incidence - United States 1996. MMWR 1997, 46:861-867.
16. Hogg RS, Rhone SA, Yip B, et al.: Antiviral effect of double and triple combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998, 12:279-284.
17. Rozenbaum W, Adda N, Wirbel E, Hadacek B, Schneider V, Costagliola D: Predictors and incidence of failure in 500 advanced stage HIV patients treated with indinavir. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 420].
18. Fatkenheuer G, Theisen A, Rockstroh J, et al.: Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
19. th Interscience Conference on Antimicrobial Agents and Chemotheraphy. Toronto, September 1997 [abstract A-14].
20. Rachlis AR, Zarowny DP, for the Canadian HIV Trials Network Antiviral Working Group: Guidelines for antiretroviral therapy for HIV infection. CMAJ 1998, 158:496-505.
21. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-486.
22. Cox DR, Oakes D: Analysis of Survival Data. London: Chapman and Hall; 1984.
23. SAS Institute, Inc.: SAS/STAT Users guide, Version 6, 5th Edn, Vol 2. Cary: SAS Institute, Inc.; 1989.
24. Goebel F, on behalf of the AVANTI Study Group: AVANTI II. A randomised double-blind comparative trial to evaluate combination antiretroviral regimens for the treatment of HIV-1 infection: AZT/3TC vs AZT/3TC/indinavir in antiretroviral naive patients. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 211].
25. 3. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 [abstract LB6A].
26. Demeter L, Hughes M, Fischl M, et al.: Predictors of virological and clinical response to indinavir (IDV) + ZDV + 3TC or ZDV + 3TC. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 509].
27. Fessel WJ, Hurley LB: Outcomes of triple therapy that included a protease. Fifth Conference on Retroviruses Opportunistic Infections. Chicago, February 1998 [abstract 145].
28. Yu G, Chang Y, Greenberg SL, et al.: Durability of virological response in patients with Viracept (Nelfinavir mesylate) in combination with zidovudine and lamivudine. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 410].
29. De Gruttola V, Hughes MD, Gilbert P, et al.: Trial design in the era of highly effective antiviral drug combinations for HIV infection. AIDS 1998, 12(Suppl. A):S144-S156.
30. Hill A, Opravil M, Demas R: Prediction of long-term HIV-1 RNA suppression during AZT/3TC treatment. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 112].
31. Perez-Elias MJ, Antela A, Casado JL, et al.: Comparison between protease inhibitor therapy with or without new nucleoside analogues. Sixth European Conference on Clinical Aspects and Treatment of HIV Infection. Hamburg, October 1997 [abstract 361].
32. Moyle G: Saquinavir: a review of its development, pharmacological properties and clinical use. Exp Opin Invest Drugs 1996, 5:155-167.
33. Mitsuyasu RT, Skolnik PR, Cohen SR et al.: Activity of the soft gelatin formulation of saquinavir in antiretroviral naive patients. AIDS 1998, 12:F103-F109.